Clinical Trials Logo

Remission clinical trials

View clinical trials related to Remission.

Filter by:

NCT ID: NCT05116228 Terminated - Clinical trials for Rheumatoid Arthritis

Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission

REDOREM
Start date: September 1, 2015
Phase: Phase 4
Study type: Interventional

To investigate whether a reduced-dose dosing regimen (1x500mg semiannually) of rituximab (RTX) (Mabthera®) is non-inferior in patients with rheumatoid arthritis (RA) whose disease is in persistent low disease activity (LDA) or clinical remission (REM) (pLDA/pREM) as compared to the standard dosing regimen of 1x1000mg semi-annual infusions.

NCT ID: NCT04986124 Recruiting - Clinical trials for Major Depressive Disorder

Quality of Life in Chinese Working and School Age Population With MDD

Start date: April 1, 2021
Phase:
Study type: Observational [Patient Registry]

Major depressive disorder (MDD) is a common mental illness with high prevalence and global burden. Previous studies revealed that over 70% patients in remission still had decreased quality of life, severe function impairment, low positive mental health score and poor coping ability. However, few studies focus on working and school age patients with MDD. A GBD survey showed that over 40% MDD patients are 15-50 years old. Therefore, we initiate the present multi-center cross-sectional survey to investigate the associations between clinical symptoms, cognitive function, occupational/study ability, and quality of life in Chinese working and school age population with MDD who are in remission.

NCT ID: NCT04916249 Active, not recruiting - Cancer Clinical Trials

Testing an Herbal Pain Relief Patch to Reduce Pain in Cancer Survivors

Start date: May 28, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether Tibetree Pain Relieving Plaster, an herbal pain relief patch, may be able to reduce this pain. Tibetree Pain Relieving Plaster is available as an over-the-counter (non-prescription) treatment for the temporary relief of minor aches and pains in muscles and joints. This study is the first to test this treatment in people who have had cancer.

NCT ID: NCT03831750 Completed - Clinical trials for Inflammatory Bowel Diseases

Assessing the Effectiveness of a Stress Reduction Intervention in Inflammatory Bowel Disease (IBD)

Start date: February 22, 2019
Phase: N/A
Study type: Interventional

The investigators have designed a guided, online, tri-component, stress reduction intervention for participants with inflammatory bowel diseases.

NCT ID: NCT03574948 Completed - Ulcerative Colitis Clinical Trials

5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores

TRP-IBD
Start date: December 6, 2018
Phase: Phase 2
Study type: Interventional

This placebo cross-over trial aims to study the effect of the oral intake of an essential amino-acid 5-OH tryptophan, the precursor of serotonin, on the fatigue scores in IBD patients in deep clinical and biological remission.

NCT ID: NCT03518814 Completed - Remission Clinical Trials

Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM)

QUALM
Start date: April 9, 2018
Phase:
Study type: Observational

Few studies have been conducted on the quality of life of patients with stage IV melanoma. Particularly, there is no data regarding the quality of life of patients with a multimetastatic melanoma currently in remission. Then, the main objective of this study is to evaluate the quality of life from a point of view medico-psycho-social in patients with multimetastatic melanoma in remission for more than 6 months.

NCT ID: NCT03261206 Active, not recruiting - Crohn Disease Clinical Trials

Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

STATIC
Start date: November 20, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess whether withdrawal of aminosalicylate (5-ASA) is non-inferior to continuation of 5-ASA therapy in Crohn's disease (CD) subjects in remission.

NCT ID: NCT03248180 Recruiting - Psychosis Clinical Trials

Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States

GDR
Start date: July 24, 2017
Phase: N/A
Study type: Observational

A 2-year prospective observational study comparing a group of patients in remitted states of psychosis undergoing guided antipsychotic dose reduction to a similar group of patients under maintenance antipsychotic treatment with the main outcome of interest that if the rates of relapse of psychosis between these two groups will be different.

NCT ID: NCT03176875 Recruiting - Crohn Disease Clinical Trials

Comparison of Partial and Exclusive Enteral Nutrition in the Treatment of Active Childhood-onset Crohn's Disease

Start date: May 25, 2017
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine the efficacy of a novel enteral nutrition (EN) protocol (delivering 75% of patient's caloric needs through EN) for induction of remission in patients with active childhood-onset Crohn's disease (CD) and compare it to the standard protocol with exclusive enteral nutrition (EEN). This novel approach allows patients to consume remaining calories (25%) from an antiinflammatory diet for CD (AID-CD). The hypothesis is that no significant difference in the remission rate between the novel EN protocol with partial enteral nutrition (PEN) and standard protocol with EEN will be observed.

NCT ID: NCT03123640 Completed - Clinical trials for Drug-Related Side Effects and Adverse Reactions

Improving Drug Safety in Emergency Patients -a Randomized Controlled Trial

EPIMERR
Start date: April 24, 2017
Phase: N/A
Study type: Interventional

Aim/Objective: Investigate the effect of implementing a working model for performing medication reconciliation (MR) and medication review (MRe) in the emergency department (ED), on readmissions, patient safety and efficiency of the stay in the ED and the hospital. Research design: randomized, controlled, non-blinded trial. Control group; standard care. Intervention group; MR and MRe performed at admission to the ED by a clinical pharmacist in the interdisciplinary team. The intervention is based on a working model for MR, developed in our initiation project, and it will be adapted to also include MRe. Key challenges in this research field: Currently no implemented systematic model ensuring that the patient's correct medication list is obtained and assessed at the point of admission. There is lack of studies investigating the clinically outcome of performing MR and MRe in the ED. Lack of knowledge on the extent of drug related hospital admissions in Norway. These challenges are also recognized and prioritized by the Norwegian authorities. Impact and utility: The results from this study will give important answers to the challenges listed above. The results could imply a huge impact on how to organize ED in Norway regarding drug safety. If the hypothesis of this study is confirmed, implementing the intervention described will increase patient safety, both the hospital and society can reduce health care expenses from readmissions, and also the readmission-burden can be reduced for the patients.